[
    [
        {
            "time": "2018-09-18",
            "original_text": "格隆汇港股聚焦(9.18)︱通达集团拟分拆公司于深交所独立上市 四川成渝8月通行费收入升4.85%至4.07亿元",
            "features": {
                "keywords": [
                    "通达集团",
                    "分拆",
                    "深交所",
                    "四川成渝",
                    "通行费收入"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "交通运输",
                    "基础设施"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(9.18)︱通达集团拟分拆公司于深交所独立上市 四川成渝8月通行费收入升4.85%至4.07亿元",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-18",
            "original_text": "上海医药(601607.SH)：控股股东上实集团再增持6.4万股H股",
            "features": {
                "keywords": [
                    "上海医药",
                    "上实集团",
                    "增持",
                    "H股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(601607.SH)：控股股东上实集团再增持6.4万股H股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-18",
            "original_text": "上海医药(02607.HK)控股股东上实集团增持6.4万股H股",
            "features": {
                "keywords": [
                    "上海医药",
                    "上实集团",
                    "增持",
                    "H股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药(02607.HK)控股股东上实集团增持6.4万股H股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-18",
            "original_text": "大动作！上海医药引进6款重磅生物药 PD-1、阿达木单抗在列",
            "features": {
                "keywords": [
                    "上海医药",
                    "生物药",
                    "PD-1",
                    "阿达木单抗"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "大动作！上海医药引进6款重磅生物药 PD-1、阿达木单抗在列",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-18",
            "original_text": "上海医药与俄药企投4亿美金设合资公司 将引6个生物药入华",
            "features": {
                "keywords": [
                    "上海医药",
                    "俄药企",
                    "合资公司",
                    "生物药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "国际合作"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药与俄药企投4亿美金设合资公司 将引6个生物药入华",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-18",
            "original_text": "上海医药与BIOCAD设合资公司 首批6个生物药将陆续投放大中华区",
            "features": {
                "keywords": [
                    "上海医药",
                    "BIOCAD",
                    "合资公司",
                    "生物药",
                    "大中华区"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技",
                    "国际合作"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海医药与BIOCAD设合资公司 首批6个生物药将陆续投放大中华区",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-18",
            "original_text": "早间公告：二三四五股东浙富控股拟减持公司股份",
            "features": {
                "keywords": [
                    "二三四五",
                    "浙富控股",
                    "减持"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "互联网"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "早间公告：二三四五股东浙富控股拟减持公司股份",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]